Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 693260, 12 pages
http://dx.doi.org/10.1155/2015/693260
Research Article

Genetic Deletion of Soluble Epoxide Hydrolase Attenuates Inflammation and Fibrosis in Experimental Obstructive Nephropathy

1Department of Physiology, National Yang-Ming University, Taipei 11221, Taiwan
2Institute of Anatomy and Cell Biology, National Yang-Ming University, Taipei 11221, Taiwan
3Division of Nephrology, Department of Medicine and Immunology Research Centre, Taipei Veterans General Hospital, Taipei 11221, Taiwan
4Division of Nephrology, Buddhist Tzu Chi General Hospital, Taipei Branch, Taipei 23142, Taiwan
5Department of Nursing, Chang Gung Institute of Technology, Taoyuan 33303, Taiwan

Received 29 September 2014; Revised 28 November 2014; Accepted 7 December 2014

Academic Editor: Tânia Silvia Fröde

Copyright © 2015 Chin-Wei Chiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Wilson, “Pathophysiology of obstructive nephropathy,” Kidney International, vol. 18, no. 3, pp. 281–292, 1980. View at Publisher · View at Google Scholar
  2. C. M. Porth, Essentials of Pathophysiology, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 3rd edition, 2010.
  3. G. F. Schreiner, K. P. G. Harris, M. L. Purkerson, and S. Klahr, “Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney,” Kidney International, vol. 34, no. 4, pp. 487–493, 1988. View at Publisher · View at Google Scholar · View at Scopus
  4. M. T. Grande and J. M. López-Novoa, “Fibroblast activation and myofibroblast generation in obstructive nephropathy,” Nature Reviews Nephrology, vol. 5, no. 6, pp. 319–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Bascands and J. P. Schanstra, “Obstructive nephropathy: insights from genetically engineered animals,” Kidney International, vol. 68, no. 3, pp. 925–937, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. L. Chevalier, “Obstructive nephropathy: towards biomarker discovery and gene therapy,” Nature Clinical Practice Nephrology, vol. 2, no. 3, pp. 157–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. E. Enayetallah, R. A. French, and D. F. Grant, “Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms,” Journal of Molecular Histology, vol. 37, no. 3-4, pp. 133–141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Spector and A. W. Norris, “Action of epoxyeicosatrienoic acids on cellular function,” American Journal of Physiology—Cell Physiology, vol. 292, no. 3, pp. C996–C1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Zhao, T. Yamamoto, J. W. Newman et al., “Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage,” Journal of the American Society of Nephrology, vol. 15, no. 5, pp. 1244–1253, 2004. View at Google Scholar · View at Scopus
  10. A. R. Kompa, B. H. Wang, G. Xu et al., “Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction,” International Journal of Cardiology, vol. 167, no. 1, pp. 210–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. A. Elmarakby, J. Faulkner, M. Al-Shabrawey, M.-H. Wang, K. R. Maddipati, and J. D. Imig, “Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 301, no. 5, pp. R1307–R1317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Fang, “Soluble epoxide hydrolase: a novel target for the treatment of hypertension,” Recent Patents on Cardiovascular Drug Discovery, vol. 1, no. 1, pp. 67–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Chevalier, M. S. Forbes, and B. A. Thornhill, “Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy,” Kidney International, vol. 75, no. 11, pp. 1145–1152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. W.-Y. Chou, J.-F. Zhao, Y.-M. A. Chen et al., “Role of glycine N-methyltransferase in experimental ulcerative colitis,” Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 494–501, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. T. Grande, F. Pérez-Barriocanal, and J. M. Lápez-Novoa, “Role of inflammation in tbulo-interstitial damage associated to obstructive nephropathy,” Journal of Inflammation, vol. 7, article 19, 14 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Rossini and A. B. Fogo, “Mechanisms leading to progression of chronic renal injury: the interstitium,” Drug Discovery Today: Disease Mechanisms, vol. 1, no. 1, pp. 65–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. C. M. Borza and A. Pozzi, “The role of cell-extracellular matrix interactions in glomerular injury,” Experimental Cell Research, vol. 318, no. 9, pp. 1001–1010, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Zhu and Y. R. Li, “Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence,” Experimental Biology and Medicine, vol. 237, no. 5, pp. 474–480, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Jung, F. Jansen, A. Mieth et al., “Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease,” PLoS ONE, vol. 5, no. 8, Article ID e11979, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. W. G. Sanders, C. Morisseau, B. D. Hammock, A. K. Cheung, and C. M. Terry, “Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor,” The American Journal of Physiology—Cell Physiology, vol. 303, no. 3, pp. C278–C290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Ulu, B. B. Davis, H.-J. Tsai et al., “Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model,” Journal of Cardiovascular Pharmacology, vol. 52, no. 4, pp. 314–323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Liu, H. Dang, D. Li, W. Pang, B. D. Hammock, and Y. Zhu, “Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice,” PLoS ONE, vol. 7, no. 6, Article ID e39165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Bystrom, J. A. Wray, M. C. Sugden et al., “Endogenous epoxygenases are modulators of monocyte/macrophage activity,” PLoS ONE, vol. 6, no. 10, Article ID e26591, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Cavaillon, “Cytokines and macrophages,” Biomedicine and Pharmacotherapy, vol. 48, no. 10, pp. 445–453, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Kim, J. D. Imig, J. Yang, B. D. Hammock, and B. J. Padanilam, “Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation,” American Journal of Physiology Renal Physiology, vol. 307, no. 8, pp. F971–F980, 2014. View at Publisher · View at Google Scholar
  26. C. Morisseau and B. D. Hammock, “Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health,” Annual Review of Pharmacology and Toxicology, vol. 53, pp. 37–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Lee, S. H. Yang, H.-Y. Lee et al., “Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney,” PLoS ONE, vol. 7, no. 5, Article ID e37075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Kim, S. P. Yoon, M. L. Toews et al., “Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy,” The American Journal of Physiology—Renal Physiology, 2014. View at Publisher · View at Google Scholar
  29. W. Zhang, A. L. Yang, J. Liao et al., “Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice,” Digestive Diseases and Sciences, vol. 57, no. 10, pp. 2580–2591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. L. Sander, H. Jakob, K. Sommer et al., “Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model,” Langenbeck's Archives of Surgery, vol. 396, no. 8, pp. 1245–1253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. L. Sander, K. Sommer, T. Neumayer et al., “Soluble epoxide hydrolase disruption as therapeutic target for wound healing,” Journal of Surgical Research, vol. 182, no. 2, pp. 362–367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Wang, W. Pang, Z. Cui et al., “Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage,” American Journal of Physiology—Renal Physiology, vol. 304, no. 2, pp. F168–F176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Zhao, L. Tu, X. Li et al., “Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis,” Human Gene Therapy, vol. 23, no. 7, pp. 688–699, 2012. View at Publisher · View at Google Scholar · View at Scopus